Table 2 Cox regression analysis of LRIG1 loss, normal, and gain adjusted for all variables in all patients
From: LRIG1 gene copy number analysis by ddPCR and correlations to clinical factors in breast cancer
Tumor characteristic | Overall survival | Metastasis-free survival | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | |
Age at diagnosis | ||||
≤ 50 years | Reference | |||
> 50 years | 2.633 (1.802–3.848) | < 0.001 | 1.306 (0.828–2.060) | 0.251 |
Tumor subtype | ||||
ERBB2-, ER/PR+ | Reference | |||
ERBB2+, ER/PR- | 1.558 (1.003–2.420) | 0.049 | 1.915 (1.077–3.405) | 0.027 |
ERBB2+, ER/PR+ | 1.563 (0.974–2.507) | 0.064 | 1.983 (1.101–3.573) | 0.023 |
ERBB2-, ER/PR- | 1.384 (0.939–2.038) | 0.1 | 1.583 (0.936–2.679) | 0.087 |
Grade | ||||
Low (1 or 2) | Reference | |||
High (3) | 1.0 (1.0–1.0) | 0.710 | 1.583 (0.936–2.679) | 0.087 |
Tumor size | ||||
≤ 20 mm | Reference | |||
> 20 mm | 1.427 (1.067–1.908) | 0.017 | 1.151 (0.751–1.762) | 0.519 |
Nodal status | ||||
Negative | Reference | |||
Positive | 2.592 (1.840–3.651) | < 0.001 | 3.435 (2.206–5.347) | < 0.001 |
LRIG1copy number | ||||
Normal | Reference | |||
Loss | 0.964 (0.668–1.393) | 0.847 | 1.115 (0.690–1.803) | 0.657 |
Gain | 0.837 (0.550–1.274) | 0.407 | 1.041 (0.585–1.852) | 0.892 |